Skip to content
thestock.space

Phaarmasia (BSE: PHRMASI) had a P/E of 3.2× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 38% below their 52-week high. Its ROCE of 97% is the highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales grew 20% a year over 3 years, though net profit is above operating profit, which points to a one-off gain. The company has almost no debt. It is a small-cap company with a market cap of ₹56 Cr, ranked 129th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 144% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹80.00
Day high
₹82.00
Day low
₹80.00
Prev. close
₹82.00
Volume
622

Health check

4 good · 1 to check
  • ReturnsAhead

    +144.3% over a year, better than 7 of 7 peers.

  • Price tagDistorted

    A one-off gain inflates profit, so P/E isn’t comparable right now.

  • GrowthStrong

    Sales +19.7% a year over 3 years.

  • ProfitabilityStrong

    ROCE 96.5% vs peer median 17.9%.

  • Balance sheetSolid

    Debt 0.05× equity, interest covered 123.7×, Piotroski 6 of 9.

  • Red flags2 to check

    Net profit is above operating profit, so a one-off gain is likely flattering earnings.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹56 Cr, #129 of 154 in its industry by size.

Moves with the market

Beta 0.85 vs the NIFTY 50: tracks the market closely.

Key metrics

Last 12 months to Jun 2026: sales ₹49 Cr · profit ₹18 Cr
Market cap
₹56 Cr
Small cap
P/E
3.2
Industry 28.7
Price to book
2.53
Peers 4.99
Dividend yield
0.00%
ROE
114.0%
Peers 14.7%
ROCE
96.5%
Peers 17.9%
Debt to equity
0.05
Debt ₹1.12 Cr
EPS (TTM)
₹25.85
OPM (TTM)
3.8%
Net margin 36.3%
Sales growth
+20.5%
Latest quarter vs a year ago
Profit growth
+25.5%
Latest quarter vs a year ago
Price to sales
1.15
EV/EBITDA 16.4

Strengths and risks

Strengths

  • Return on equity of 114.0%.
  • Return on capital employed of 96.5%.
  • Practically debt-free.
  • Quarterly profit up 25.5% on a year ago.
  • Quarterly sales up 20.5% on a year ago.

Risks to check

  • Net profit is above operating profit, so a one-off gain is likely flattering earnings.
  • 38% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Phaarmasia

Phaarmasia Limited manufactures and sells oral contraceptive pills in India. It also engages in the manufacture and marketing of cosmetics and combi pack with iron tablets. Phaarmasia Limited was incorporated in 1981 and is based in Hyderabad, India.

Headquarters
Hyderabad
Employees
47
Sector
Healthcare
ISIN
INE486I01016
Website
phaarmasia.in

Price range

52 weeks

₹31.00₹131.75

Today

₹80.00₹82.00
Avg volume (3M)
736
1-year return
plus 144.3%
From 52-week high
minus 37.8%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
PHRMASIPhaarmasia82.000.00%563.22.5396.5%114.0%3.8%19.7%–0.00%plus 144.3%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
6.916.616.17.78.3
6.814.915.28.48.2
0.11.60.8−0.70
1.3%9.7%5.2%−8.6%0.6%
0.30.10.20.30.3
0000.20
0.10.10.100
––19––
0.31.719.9−0.50.3
13.7%−2.2%18.3%−31.1%−11.4%
0.31.716.3−0.70.3
0.402.5423.84-1.030.50

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+19.7%
ROE
114.0%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
27.530.624.447.2
–+11.3%minus 20.3%+93.7%
2931.426.445.3
−1.5−0.8−21.9
−5.6%−2.7%−8.3%4.0%
0.50.60.70.9
0000.2
0.40.30.30.2
–––19
−1.4−0.5−1.621.4
12.1%5.1%0.8%17.8%
−1.3−0.5−1.617.6
-1.84-0.76-2.3325.74

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
6.86.86.86.8
43.51.915.3
0.30.101.1
17.32112.86.8
28.431.421.630.1
12.812.412.31
0–0–
0.70.60.411
14.918.48.918.1
28.431.421.630.1

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
0.60.1−0−16.4
−0−0−0.126.1
−0.2−0.2−0.10.9
0.5−0.1−0.310.6
−0−0−0.2–
0.60.1−0.2−16.4

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you